Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Have you been told you have a condition called ‘Avascular Necrosis’ or ‘Osteonecrosis’? If so, could we talk to you about a new study that is currently being thought about?

Who are we?

We are a team of university researchers, surgeons, rheumatologists and nurses wanting to investigate which drugs might better help people with ‘Avascular Necrosis’ or ‘Osteonecrosis’. 

Who are we looking for?

The National Institute for Health Research is looking to fund a study to decide if one drug or a combination of drugs might improve pain and movement for individuals with these painful conditions.

We would like to invite people who have experienced hip pain due to the above conditions to join us for an informal meeting to talk about the proposed study, and to ask your opinions about the study we are thinking we would run – YOU WOULD NOT BE JOINING OR BE ASKED TO JOIN THE STUDY.

Want to learn more?

Join us for a meeting on Friday 4th September in Oxford at the Botnar Research Centre at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. We will provide light refreshments and will reimburse you for your time and travel.

If you are interested in knowing more and would like to get involved, please call Vicki Barber on  01865 223463 or email vicki.barber@ndorms.ox.ac.uk                                                   

This study is supported by the Patient and Public Involvement Officer, Research Design Service South Central, National Institute for Health Research.

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.